One of the best things about a democracy is getting to vote out representatives who let us down. As shareholders, it's much harder to express dissatisfaction in management without just selling shares, since you may really like the business despite management. But some investors might wish they could vote out the CEOs of these two companies.
Shares of GlaxoSmithKline (NYSE: GSK) and Bayer (OTC: BAYRY) have lagged the market for years, and investors have a few good reasons to be fed up. The companies are making moves to transform their businesses, but are the benefits anywhere close to being realized?
Image source: Getty Images
For further details see:
Investors Wish They Could Vote These 2 Healthcare CEOs Out